NO20084539L - Humaniserte monoklonale antistoffer til hepatocyttvekstfaktor - Google Patents

Humaniserte monoklonale antistoffer til hepatocyttvekstfaktor

Info

Publication number
NO20084539L
NO20084539L NO20084539A NO20084539A NO20084539L NO 20084539 L NO20084539 L NO 20084539L NO 20084539 A NO20084539 A NO 20084539A NO 20084539 A NO20084539 A NO 20084539A NO 20084539 L NO20084539 L NO 20084539L
Authority
NO
Norway
Prior art keywords
growth factor
hepatocyte growth
monoclonal antibodies
humanized monoclonal
composition
Prior art date
Application number
NO20084539A
Other languages
English (en)
Norwegian (no)
Inventor
Maximiliano Vasquez
Lihong Wang
Kyung Jin Kim
Hangil Park
Original Assignee
Galaxy Biotech Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galaxy Biotech Llc filed Critical Galaxy Biotech Llc
Publication of NO20084539L publication Critical patent/NO20084539L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
NO20084539A 2006-04-01 2008-10-28 Humaniserte monoklonale antistoffer til hepatocyttvekstfaktor NO20084539L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78824306P 2006-04-01 2006-04-01
PCT/US2007/065385 WO2007115049A2 (en) 2006-04-01 2007-03-28 Humanized monoclonal antibodies to hepatocyte growth factor

Publications (1)

Publication Number Publication Date
NO20084539L true NO20084539L (no) 2008-10-28

Family

ID=38564195

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20084539A NO20084539L (no) 2006-04-01 2008-10-28 Humaniserte monoklonale antistoffer til hepatocyttvekstfaktor

Country Status (25)

Country Link
US (3) US7632926B2 (OSRAM)
EP (2) EP2016162B1 (OSRAM)
JP (1) JP5312315B2 (OSRAM)
KR (1) KR101516289B1 (OSRAM)
CN (2) CN103172736A (OSRAM)
AR (1) AR059922A1 (OSRAM)
AU (1) AU2007233242B2 (OSRAM)
BR (1) BRPI0709932A2 (OSRAM)
CA (1) CA2645358C (OSRAM)
CO (1) CO6140067A2 (OSRAM)
CR (1) CR10308A (OSRAM)
ES (1) ES2465668T3 (OSRAM)
GE (1) GEP20125517B (OSRAM)
IL (1) IL194221A (OSRAM)
MA (1) MA30382B1 (OSRAM)
MX (1) MX2008012619A (OSRAM)
MY (1) MY145042A (OSRAM)
NO (1) NO20084539L (OSRAM)
NZ (1) NZ571132A (OSRAM)
PE (1) PE20080008A1 (OSRAM)
RU (1) RU2461570C2 (OSRAM)
TW (1) TWI417300B (OSRAM)
UA (1) UA94452C2 (OSRAM)
WO (1) WO2007115049A2 (OSRAM)
ZA (1) ZA200807903B (OSRAM)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040208876A1 (en) * 2003-04-18 2004-10-21 Kim Kyung Jin Monoclonal antibodies to hepatocyte growth factor
TW201319088A (zh) 2003-07-18 2013-05-16 Amgen Inc 對肝細胞生長因子具專一性之結合劑
JP2008545753A (ja) * 2005-06-02 2008-12-18 ギャラクシー バイオテック， エルエルシー 抗体で脳腫瘍を処置する方法
AR059922A1 (es) 2006-04-01 2008-05-07 Galaxy Biotech Llc Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos
PL2027156T3 (pl) 2006-06-02 2011-06-30 Aveo Pharmaceuticals Inc Białka wiążące czynnik wzrostowy hapatocytów (HGF)
AR061170A1 (es) 2006-06-02 2008-08-06 Aveo Pharmaceuticals Inc Proteinas que se unen con el factor de crecimiento de hepatocitos (hgf)
PL2032166T3 (pl) 2006-06-13 2013-09-30 Oncomed Pharm Inc Kompozycje i sposoby diagnozowania i leczenia nowotworów
CA2676008A1 (en) 2007-01-24 2008-07-31 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
SG188802A1 (en) * 2008-03-06 2013-04-30 Genentech Inc Combination therapy with c-met and egfr antagonists
EP2274153B1 (en) * 2008-04-10 2012-07-04 Objet Ltd. System and method for three dimensional model printing
US20110217294A1 (en) * 2008-04-11 2011-09-08 Daniel Fults Combination of hgf inhibitor and hedgehog inhibitor to treat cancer
TW201002346A (en) * 2008-04-11 2010-01-16 Galaxy Biotech Llc Combination of HGF inhibitor and EGF inhibitor to treat cancer
PE20091714A1 (es) * 2008-04-11 2009-11-15 Galaxy Biotech Llc Combinacion del inhibidor hgf y el agonista pten
EP2288383A1 (en) * 2008-05-14 2011-03-02 Amgen, Inc Combinations vegf(r) inhibitors and hepatocyte growth factor (c-met) inhibitors for the treatment of cancer
AU2009255305B2 (en) 2008-05-29 2014-10-30 Galaxy Biotech, Llc Monoclonal antibodies to basic fibroblast growth factor
CN102316897B (zh) 2008-07-08 2014-11-05 昂考梅德药品有限公司 Notch结合剂和拮抗剂及其应用方法
US9132189B2 (en) 2008-07-08 2015-09-15 Oncomed Pharmaceuticals, Inc. Notch1 binding agents and methods of use thereof
MX2011000455A (es) 2008-11-07 2011-02-25 Galaxy Biotech Llc Anticuerpos monoclonales especificos al receptor 2 del factor de crecimiento de fibroblastos.
US8497358B2 (en) 2008-12-19 2013-07-30 Takeda Pharmaceutical Company Limited Antibody purification method
US20120052064A1 (en) 2009-04-17 2012-03-01 Yuuki Ito Anti-hgf antibody combinational cancer therapies
CA2763488A1 (en) * 2009-05-28 2010-12-02 Neil James Clarke Antigen-binding proteins
AU2011205316B2 (en) 2010-01-13 2015-05-28 Oncomed Pharmaceuticals, Inc. Notch1 binding agents and methods of use thereof
EP3511342B1 (en) 2010-03-10 2024-01-17 Genmab A/S Monoclonal antibodies against c-met
WO2012003338A1 (en) 2010-07-01 2012-01-05 Takeda Pharmaceutical Company Limited COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET
US20140057908A1 (en) 2010-09-27 2014-02-27 Exelixis, Inc. Method of Treating Cancer
EP2853542A1 (en) * 2010-11-24 2015-04-01 Glaxo Group Limited Multispecific antigen binding proteins targeting HGF
AU2012304362A1 (en) 2011-09-09 2014-03-06 Amgen Inc. Use of c-Met protein for predicting the efficacy of anti-hepatocyte growth factor ("HGF") antibodies in esophageal and gastric cancer patients
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
EP2873422A4 (en) 2012-07-10 2015-12-30 Takeda Pharmaceutical PHARMACEUTICAL PREPARATION FOR INJECTION
EP2708556B1 (en) 2012-09-12 2018-11-07 Samsung Electronics Co., Ltd Pharmaceutical composition for the use in a combination therapy for prevention or treatment of c-met or angiogenesis factor induced diseases
US9062104B2 (en) 2013-03-14 2015-06-23 Alderbio Holdings Llc Therapeutic use of antibodies to HGF
US9732150B2 (en) 2013-03-14 2017-08-15 Alderbio Holdings Llc Therapeutic use of antibodies to HGF
TW201438737A (zh) * 2013-03-14 2014-10-16 Alder Biopharmaceuticals Inc Ｈｇｆ抗體之治療用途
EP3122900A1 (en) 2014-03-24 2017-02-01 F. Hoffmann-La Roche AG Cancer treatment with c-met antagonists and correlation of the latter with hgf expression
KR102791773B1 (ko) 2015-10-30 2025-04-03 갤럭시 바이오테크, 엘엘씨 사멸 수용체 4 및 사멸 수용체 5에 결합하는 매우 강력한 항체
EP4043492A1 (en) 2016-03-01 2022-08-17 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Antibodies specific to human poliovirus receptor (pvr)
JP2022543555A (ja) 2019-08-12 2022-10-13 インテアールエヌエー テクノロジーズ ビー．ヴイ． ｍｉＲＮＡ－１９３ａに関する新たな処置
AU2021227002A1 (en) 2020-02-28 2022-09-15 Interna Technologies B.V. miRNA-193a for promoting immunogenic cell death
CN113980129B (zh) * 2021-01-15 2023-07-28 东大生物技术(苏州)有限公司 一组il-11单克隆抗体及其医药用途
CN119285785B (zh) * 2024-09-26 2025-04-18 武汉奥科博泰生物科技有限公司 一种抗d-二聚体单克隆抗体及其应用

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2564486B2 (ja) * 1986-07-14 1996-12-18 修治 橋本 肝細胞増殖因子
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
ATE139258T1 (de) 1990-01-12 1996-06-15 Cell Genesys Inc Erzeugung xenogener antikörper
GB9009548D0 (en) 1990-04-27 1990-06-20 Celltech Ltd Chimeric antibody and method
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
DK0585287T3 (da) 1990-07-10 2000-04-17 Cambridge Antibody Tech Fremgangsmåde til fremstilling af specifikke bindingsparelementer
EP0940468A1 (en) * 1991-06-14 1999-09-08 Genentech, Inc. Humanized antibody variable domain
EP0746609A4 (en) 1991-12-17 1997-12-17 Genpharm Int NON-HUMAN TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGOUS ANTIBODIES
US5837676A (en) * 1993-10-18 1998-11-17 Long Island Jewish Medical Center Use of scatter factor to enhance angiogenesis
US6498144B1 (en) * 1993-10-18 2002-12-24 North Shore - Long Island Jewish Research Institute Use of scatter factor to enhance angiogenesis
US5707624A (en) * 1994-06-03 1998-01-13 The Regents Of The University Of Michigan Treatment of Kaposi's sarcoma by inhibition of scatter factor
US6214344B1 (en) * 1995-06-02 2001-04-10 Genetech, Inc. Hepatocyte growth factor receptor antagonists and uses thereof
US5646036A (en) * 1995-06-02 1997-07-08 Genentech, Inc. Nucleic acids encoding hepatocyte growth factor receptor antagonist antibodies
US5686292A (en) * 1995-06-02 1997-11-11 Genentech, Inc. Hepatocyte growth factor receptor antagonist antibodies and uses thereof
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
JP2000515735A (ja) * 1996-07-03 2000-11-28 ジェネンテック インコーポレーテッド 肝細胞成長因子レセプターアゴニスト
DE60029953T2 (de) * 1999-05-17 2007-09-13 Avi Biopharma, Inc., Corvallis Spezifische Antikörper gegen humanes Choriongonadotropin und deren Verwendung in Therapie und Diagnose
WO2001034650A1 (en) 1999-11-09 2001-05-17 The Government Of The United States Of America, As Represented By The Secretary, Department Of Heatlh And Human Services Hgf-sf monoclonal antibody combinations
EP1423432A4 (en) 2001-07-26 2006-01-11 Lilly Co Eli ANTIBODIES TO INTERLEUKIN 1 BETA (IL-1BETA)
JP2005527488A (ja) 2001-12-27 2005-09-15 バン アンデル リサーチ インスティチュート Ｍｅｔを発現し、肝細胞増殖因子と結合する腫瘍のモノクローナル抗体画像化および治療
WO2004019991A2 (en) * 2002-08-30 2004-03-11 F. Hoffmann-La Roche Ag Scatter factor/hepatocyte growth factor antagonist nk4 for the treatment of glioma
AU2003900180A0 (en) * 2003-01-16 2003-01-30 Silverbrook Research Pty Ltd Method and apparatus (dam001)
US7220410B2 (en) 2003-04-18 2007-05-22 Galaxy Biotech, Llc Monoclonal antibodies to hepatocyte growth factor
US20040208876A1 (en) 2003-04-18 2004-10-21 Kim Kyung Jin Monoclonal antibodies to hepatocyte growth factor
ES2323425T3 (es) 2003-06-06 2009-07-15 Genentech, Inc. Modulacion de la interaccion entre la cadena beta de hgf y c-met.
ATE451115T1 (de) 2003-07-07 2009-12-15 Van Andel Res Inst Hemmung der tumor-angiogenese durch eine kombination von thrombospondin-1 und hemmern des vaskulären endothel-wachstumsfaktors
TW201319088A (zh) 2003-07-18 2013-05-16 Amgen Inc 對肝細胞生長因子具專一性之結合劑
WO2005027107A1 (en) 2003-09-18 2005-03-24 Koninklijke Philips Electronics N.V. Information carrier and system for reading data stored on such an information carrier
CA2744997A1 (en) 2003-09-26 2005-04-07 Exelixis, Inc. C-met modulators and method of use
KR100556660B1 (ko) 2003-11-11 2006-03-10 국립암센터 Ｈｇｆ의 중화가능 에피토프 및 이에 결합하는 중화 항체
US7708991B2 (en) * 2004-02-17 2010-05-04 Stc.Unm Method for treating cancer and identifying novel anti-cancer compounds
AU2005270068B2 (en) 2004-07-02 2012-04-19 Exelixis, Inc. C-Met modulators and method of use
JP2008545753A (ja) 2005-06-02 2008-12-18 ギャラクシー バイオテック， エルエルシー 抗体で脳腫瘍を処置する方法
US7964365B2 (en) 2005-11-08 2011-06-21 The United States of Americam as represented by the Secretary, Department of Health and Human Services Methods for diagnosing and monitoring the progression of cancer
AR059922A1 (es) 2006-04-01 2008-05-07 Galaxy Biotech Llc Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos

Also Published As

Publication number Publication date
EP2476704A2 (en) 2012-07-18
JP5312315B2 (ja) 2013-10-09
AU2007233242A1 (en) 2007-10-11
MX2008012619A (es) 2008-10-13
US20140335076A1 (en) 2014-11-13
US20080019974A1 (en) 2008-01-24
AR059922A1 (es) 2008-05-07
CA2645358A1 (en) 2007-10-11
TW200808828A (en) 2008-02-16
US20100278815A1 (en) 2010-11-04
ZA200807903B (en) 2010-03-31
WO2007115049A2 (en) 2007-10-11
UA94452C2 (ru) 2011-05-10
EP2016162B1 (en) 2014-04-16
CN103172736A (zh) 2013-06-26
MY145042A (en) 2011-12-15
CN101415811A (zh) 2009-04-22
PE20080008A1 (es) 2008-02-14
AU2007233242B2 (en) 2012-04-26
EP2016162A2 (en) 2009-01-21
TWI417300B (zh) 2013-12-01
KR101516289B1 (ko) 2015-05-07
CN101415811B (zh) 2013-01-30
EP2476704A3 (en) 2012-07-25
CA2645358C (en) 2015-05-05
WO2007115049A3 (en) 2008-09-04
HK1121489A1 (en) 2009-04-24
JP2009532378A (ja) 2009-09-10
GEP20125517B (en) 2012-05-25
US8628778B2 (en) 2014-01-14
EP2016162A4 (en) 2009-11-11
CR10308A (es) 2008-10-27
RU2008143318A (ru) 2010-05-10
RU2461570C2 (ru) 2012-09-20
NZ571132A (en) 2012-05-25
US7632926B2 (en) 2009-12-15
ES2465668T3 (es) 2014-06-06
BRPI0709932A2 (pt) 2011-08-02
CO6140067A2 (es) 2010-03-19
MA30382B1 (fr) 2009-05-04
KR20090013777A (ko) 2009-02-05
IL194221A (en) 2015-11-30

Similar Documents

Publication Publication Date Title
NO20084539L (no) Humaniserte monoklonale antistoffer til hepatocyttvekstfaktor
DK1734995T3 (da) Monoklonale antistoffer og hepatocyytvækstfaktor
CY1115456T1 (el) Μεθοδος χορηγησης αντισωματων αντι-ιl-5
UA109633C2 (uk) Антитіло людини проти тканинного фактора
EA200702053A1 (ru) Антитела против cd38 для лечения множественной миеломы
GEP20196963B (en) Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors
EA200970335A1 (ru) Композиции и способы для диагностики и лечения рака
NO20083895L (no) Anti-IGF-1R human monoklonalantibody formulering
EA201170590A1 (ru) Ингибиторы рецептора фактора роста фибробластов-3 (fgfr-3) и способы лечения
MY182680A (en) Antibody formulation and therapeutic regimens
MA29595B1 (fr) Anticorps anti-cd40 humanises et procedes d'utilisation
UA90457C2 (ru) Человеческое моноклональное антитело, которое специфически связывается с м-csf человека и блокирует связывание м-csf с с-fms
TN2010000210A1 (en) Monoclonal antibodies that bind to hgm-csf and medical compositions comprising same
UA113623C2 (uk) Моноклональне антитіло проти інгібітору шляху тканинного фактора (tfpi)
MY169272A (en) Her2 antibody composition
GEP20094829B (en) Fully human antibodies against human 4-1bb (cd137)
NZ602166A (en) Antibodies to il-6 and use thereof
UA94899C2 (ru) Фиксированное дозирование антител к her
CA2725873A1 (en) Monoclonal antibodies to basic fibroblast growth factor
DK2109623T3 (da) Cancerbehandling med anti-IL-1-antistoffer
MX2021010453A (es) Conjugados anticuerpo-farmaco que comprenden anticuerpos contra dlk1 humana y uso de estos.
EA201100884A1 (ru) Моноклональные антитела анти-rhd
ATE437186T1 (de) Anti-epcam-immunoglobuline
WO2010094981A3 (en) Antibody therapy
NO20055312L (no) Farmasoytisk sammensetning omfattende et biospesifikt antistoff for EPCAM

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application